welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy

key information

study id #: NCT02752048

condition: Duchenne Muscular Dystrophy

status: completed


The objective of this study is to evaluate the efficacy after 24-week repeated oral doses of TAS-205 in patients with Duchenne Muscular Dystrophy (DMD) in an exploratory manner.

intervention: TAS-205, Placebo

mechanism of action: HPGDS inhibitor to modulate effects of inflammation

results: https://clinicaltrials.gov/ct2/show/results/NCT02752048

last updated: May 03, 2020